TABLE OF CONTENTS
1 INTRODUCTION 38
1.1 OBJECTIVES OF THE STUDY 38
1.2 MARKET DEFINITION 38
1.3 OVERVIEW 38
1.4 CURRENCY AND PRICING 40
1.5 LIMITATIONS 40
1.6 MARKETS COVERED 41
2 MARKET SEGMENTATION 44
2.1 MARKETS COVERED 44
2.2 GEOGRAPHICAL SCOPE 45
2.3 YEARS CONSIDERED FOR THE STUDY 46
2.4 DBMR TRIPOD DATA VALIDATION MODEL 47
2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 50
2.6 MULTIVARIATE MODELLING 51
2.7 MARKET APPLICATION COVERAGE GRID 52
2.8 PRODUCT LIFELINE CURVE 53
2.9 DBMR MARKET POSITION GRID 54
2.10 VENDOR SHARE ANALYSIS 56
2.11 SECONDARY SOURCES 57
2.12 ASSUMPTIONS 57
3 EXECUTIVE SUMMARY 58
4 PREMIUM INSIGHTS 61
4.1 PORTERS FIVE FORCES 62
4.2 PESTEL ANALYSIS 63
4.3 INDUSTRY INSIGHTS 64
4.4 CONCLUSION 65
5 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET: REGULATORY FRAMEWORK 66
6 MARKET OVERVIEW 68
6.1 DRIVERS 70
6.1.1 GROWING BURDEN OF GENETIC DISORDERS AS WELL AS CANCER 70
6.1.2 INNOVATION AND ADVANCEMENTS IN FISH PRODUCTS 70
6.1.3 HIGH FUNDING FOR RESEARCH ACTIVITIES 71
6.1.4 RISING DEMAND AND USAGE OF FISH TECHNIQUES 71
6.2 RESTRAINTS 72
6.2.1 HIGH COST OF FISH TESTING 72
6.2.2 LIMITED AVAILABILITY OF SKILLED PROFESSIONALS 72
6.3 OPPORTUNITIES 73
6.3.1 RISING PUBLIC AWARENESS ABOUT THE EARLY DETECTION OF GENETIC ABNORMALITIES 73
6.3.2 RISE IN DEVELOPMENT OF SPECIFIC BIOMARKERS AND VARIOUS PROBES 73
6.4 CHALLENGES 74
6.4.1 STRINGENT GOVERNMENT REGULATIONS FOR THE APPROVAL OF FISH PROBES 74
6.4.2 ETHICAL CONCERNS ASSOCIATED WITH FISH TECHNOLOGY 74
7 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY PRODUCT TYPE 75
7.1 OVERVIEW 76
7.2 CONSUMABLES 79
7.2.1 FISH PROBE 79
7.2.1.1 FISH PROBE, BY PROBE TYPE 80
7.2.1.1.1 CHROMOSOME FISH PROBE 80
7.2.1.1.2 SPLIT FISH PROBES 80
7.2.1.1.3 TRANSLOCATION FISH PROBES 80
7.2.1.1.4 SUBTELOMERE FISH PROBES 80
7.2.1.1.5 PRENATAL FISH PROBES 80
7.2.1.1.6 OTHERS PROBES 81
7.2.1.2 FISH PROBE, BY TECHNOLOGY 81
7.2.1.2.1 FLOW FLUORESCENT IN SITU HYBRIDIZATION 81
7.2.1.2.2 C-ISH 81
7.2.1.2.3 D-ISH 81
7.2.1.2.4 Q- FLUORESCENT IN SITU HYBRIDIZATION 81
7.2.1.2.5 OTHERS 81
7.2.1.3 FISH PROBE, BY TYPE 82
7.2.1.3.1 RNA 82
7.2.1.3.1.1 MRNA 82
7.2.1.3.1.2 MIRNA 82
7.2.1.3.1.3 OTHERS 83
7.2.1.3.2 DNA 83
7.2.2 ACCESSORY KITS & REAGENTS 83
7.2.2.1 KITS 83
7.2.2.2 BUFFER 83
7.2.2.3 DYES 83
7.2.2.4 OTHERS 84
7.3 INSTRUMENT 84
7.3.1 STANDALONE 85
7.3.2 PORTABLE 85
7.3.3 HANDHELD 85
7.4 SOFTWARE 85
8 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY TECHNOLOGY 86
8.1 OVERVIEW 87
8.2 RNA FLUORESCENT IN SITU HYBRIDIZATION 90
8.3 DNA FLUORESCENT IN SITU HYBRIDIZATION 91
8.4 PNA FLUORESCENT IN SITU HYBRIDIZATION 92
8.5 OTHERS 93
9 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY APPLICATION 94
9.1 OVERVIEW 95
9.2 CANCER RESEARCH 98
9.2.1 CANCER RESEARCH, BY CANCER TYPE 99
9.2.1.1 NON-HEMATOPOETIC MALIGNANCIES (SOLID TUMORS) 99
9.2.1.1.1 BREAST CANCER 99
9.2.1.1.2 LUNG CANCER 99
9.2.1.1.3 MELANOMA 100
9.2.1.1.4 PROSTRATE CANCER 100
9.2.1.1.5 OVARIAN CANCER 100
9.2.1.1.6 OTHERS 100
9.2.1.2 HEMATOPOETIC MALIGNANCIES 100
9.2.1.2.1 LEUKEMIA 100
9.2.1.2.2 MULTIPLE MYELOMA 101
9.2.1.2.3 MYELODYSPLASTIC SYNDROMES (MDS) 101
9.2.2 CANCER RESEARCH, BY PRODUCT 101
9.2.2.1 CONSUMABLES 101
9.2.2.2 INSTRUMENTS 101
9.2.2.3 SOFTWARE 101
9.3 GENETIC RESEARCH 102
9.3.1 CYTOGENETICS 103
9.3.2 CHROMOSOMAL ABNORMALITIES 103
9.3.3 OTHERS 103
9.4 INFECTIOUS DISEASE 103
9.4.1 CONSUMABLES 104
9.4.2 INSTRUMENTS 104
9.4.3 SOFTWARE 104
9.5 PERSONALIZED MEDICINE 104
9.6 OTHERS 105
10 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY USAGE 106
10.1 OVERVIEW 107
10.2 RESEARCH 110
10.2.1 INSTRUMENTS 110
10.2.2 CONSUMABLES 111
10.2.3 SOFTWARE 111
10.3 CLINICAL 111
10.3.1 CONSUMABLES 112
10.3.2 INSTRUMENT 112
10.3.3 SOFTWARE 112
10.4 COMPANION DIAGNOSTIC 112
10.4.1 CONSUMABLES 113
10.4.2 INSTRUMENT 113
10.4.3 SOFTWARE 113
11 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY END USER 114
11.1 OVERVIEW 115
11.2 DIAGNOSTIC LABORATORIES 118
11.3 HOSPITALS & CLINICS 118
11.4 PHARMACEUTICALS & BIOTECHNOLOGICAL COMPANIES 119
11.5 ACADEMIC & RESEARCH INSTITUTES 120
11.6 CONTRACT RESEARCH ORGANIZATIONS 120
11.7 OTHERS 121
12 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY DISTRIBUTION CHANNEL 122
12.1 OVERVIEW 123
12.2 RETAIL SALES 126
12.3 ONLINE SALES 126
12.4 DIRECT TENDER 127
12.5 OTHERS 128
13 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, BY REGION 129
13.1 EUROPE 130
13.1.1 GERMANY 144
13.1.2 U.K. 152
13.1.3 ITALY 160
13.1.4 FRANCE 168
13.1.5 SPAIN 176
13.1.6 RUSSIA 184
13.1.7 SWITZERLAND 192
13.1.8 TURKEY 200
13.1.9 BELGIUM 208
13.1.10 NETHERLANDS 216
13.1.11 DENMARK 224
13.1.12 SWEDEN 232
13.1.13 POLAND 240
13.1.14 NORWAY 248
13.1.15 FINLAND 256
13.1.16 REST OF EUROPE 264
14 EUROPE FLUORESCENT IN SITU HYBRIDIZATION (FISH) MARKET, COMPANY LANDSCAPE 265
14.1 COMPANY SHARE ANALYSIS: EUROPE 265
15 SWOT ANALYSIS 266
16 COMPANY PROFILE 267
16.1 MERCK KGAA 267
16.1.1 COMPANY SNAPSHOT 267
16.1.2 REVENUE ANALYSIS 267
16.1.3 COMPANY SHARE ANALYSIS 268
16.1.4 PRODUCT PORTFOLIO 268
16.1.5 RECENT DEVELOPMENT 268
16.2 ABBOTT 269
16.2.1 COMPANY SNAPSHOT 269
16.2.2 REVENUE ANALYSIS 269
16.2.3 COMPANY SHARE ANALYSIS 270
16.2.4 PRODUCT PORTFOLIO 270
16.2.5 RECENT DEVELOPMENT 271
16.3 AGILENT TECHNOLOGIES, INC. 272
16.3.1 COMPANY SNAPSHOT 272
16.3.2 REVENUE ANALYSIS 272
16.3.3 COMPANY SHARE ANALYSIS 273
16.3.4 PRODUCT PORTFOLIO 273
16.3.5 RECENT DEVELOPMENT 273
16.4 F. HOFFMANN-LA ROCHE LTD. 274
16.4.1 COMPANY SNAPSHOT 274
16.4.2 REVENUE ANALYSIS 274
16.4.3 COMPANY SHARE ANALYSIS 275
16.4.4 PRODUCT PORTFOLIO 275
16.4.5 RECENT DEVELOPMENT 275
16.5 THERMO FISCHER SCIENTIFIC INC. 276
16.5.1 COMPANY SNAPSHOT 276
16.5.2 REVENUE ANALYSIS 276
16.5.3 COMPANY SHARE ANALYSIS 277
16.5.4 PRODUCT PORTFOLIO 277
16.5.5 RECENT DEVELOPMENT 278
16.6 ABCAM PLC. 279
16.6.1 COMPANY SNAPSHOT 279
16.6.2 REVENUE ANALYSIS 279
16.6.3 COMPANY SHARE ANALYSIS 280
16.6.4 PRODUCT PORTFOLIO 280
16.6.5 RECENT DEVELOPMENTS 280
16.7 ABNOVA CORPORATION 282
16.7.1 COMPANY SNAPSHOT 282
16.7.2 PRODUCT PORTFOLIO 282
16.7.3 RECENT DEVELOPMENT 282
16.8 BIO SB 283
16.8.1 COMPANY SNAPSHOT 283
16.8.2 PRODUCT PORTFOLIO 283
16.8.3 RECENT DEVELOPMENT 283
16.9 BIOCARE MEDICAL, LLC 284
16.9.1 COMPANY SNAPSHOT 284
16.9.2 PRODUCT PORTFOLIO 284
16.9.3 RECENT DEVELOPMENT 285
16.10 BIOCAT GMBH 286
16.10.1 COMPANY SNAPSHOT 286
16.10.2 PRODUCT PORTFOLIO 286
16.10.3 RECENT DEVELOPMENT 287
16.11 BIODOT 288
16.11.1 COMPANY SNAPSHOT 288
16.11.2 PRODUCT PORTFOLIO 288
16.11.3 RECENT DEVELOPMENT 288
16.12 BIOGENEX 289
16.12.1 COMPANY SNAPSHOT 289
16.12.2 PRODUCT PORTFOLIO 289
16.12.3 RECENT DEVELOPMENT 289
16.13 BIO-TECHNE 290
16.13.1 COMPANY SNAPSHOT 290
16.13.2 REVENUE ANALYSIS 290
16.13.3 COMPANY SHARE ANALYSIS 291
16.13.4 PRODUCT PORTFOLIO 291
16.13.5 RECENT DEVELOPMENT 291
16.14 BIOZOL DIAGNOSTICS VERTRIEB GMBH 292
16.14.1 COMPANY SNAPSHOT 292
16.14.2 PRODUCT PORTFOLIO 292
16.14.3 RECENT DEVELOPMENT 293
16.15 EXCILONE 294
16.15.1 COMPANY SNAPSHOT 294
16.15.2 PRODUCT PORTFOLIO 294
16.15.3 RECENT DEVELOPMENT 294
16.16 GENEMED BIOTECHNOLOGIES, INC. 295
16.16.1 COMPANY SNAPSHOT 295
16.16.2 PRODUCT PORTFOLIO 295
16.16.3 RECENT DEVELOPMENT 295
16.17 KANEKA EUROGENTEC S.A. 296
16.17.1 COMPANY SNAPSHOT 296
16.17.2 PRODUCT PORTFOLIO 296
16.17.3 RECENT DEVELOPMENT 296
16.18 LEICA BIOSYSTEMS NUSSLOCH GMBH 297
16.18.1 COMPANY SNAPSHOT 297
16.18.2 PRODUCT PORTFOLIO 297
16.18.3 RECENT DEVELOPMENT 297
16.19 METASYSTEMS 298
16.19.1 COMPANY SNAPSHOT 298
16.19.2 PRODUCT PORTFOLIO 298
16.19.3 RECENT DEVELOPMENT 298

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.